Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases

Zhang, Zhihua; Yang, Xiaolu; Jin, Huiyi; Yuan, Qing; Zhang, Yuan; Liu, Kun; Xu, Xun

doi:10.1038/srep38326

Cited by 10 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; Zhang et al. ). However, not all patients respond to anti‐VEGF intravitreal treatment equally (Lazic et al.…”

Section: Introductionmentioning

confidence: 98%

Implication of inflammatory cytokines in the aqueous humour for management of macular diseases

Qian¹,

Wang²,

Chen³

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: To characterize profile of cytokines in aqueous humour of common macular diseases during intravitreal anti-VEGF therapy. Methods: Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy. Cytokines including vascular endothelium growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1) and interleukin 6 (IL-6) were quantitated and analysed along with retinal thickness data by optical coherence tomography (OCT) across two intravitreal injections and five macular disease types. Results: ICAM-1, IL-6 and VEGF are positively associated in the aqueous humour of naive eyes (r = 0.39-0.77, p = 0.018 to <0.0001). ICAM-1, VEGF and IL-6 were significantly higher in CRVO and DME while lowest in pmCNV (p < 0.0001). Reduction of central retinal thickness (CRT) as a favourable response to anti-VEGF therapy was in the order of CRVO, BRVO, DME and nAMD/pmCNV (p < 0.0001). The strongest predictor for favourable CRT reduction was baseline CRT (p < 0.0001) followed by baseline ICAM-1 (p = 0.04). After the 1st intravitreal anti-VEGF therapy, VEGF in aqueous humour lowered significantly but ICAM-1 and IL-6 levels remained unchanged. ICAM-1 was not predictive for CRT reduction following 2nd anti-VEGF therapy. Conclusion: Rate of cytokine production is disease-dependent and higher in CRVO and DME. Anatomical response to intravitreal anti-VEGF therapy is disease-specific and best in RVO patients. A combination therapy using both anti-VEGF and anti-inflammatory therapeutics may be superior to single anti-VEGF therapy, at least for RVO and DME.

show abstract

“…; Zhang et al. ). However, not all patients respond to anti‐VEGF intravitreal treatment equally (Lazic et al.…”

Section: Introductionmentioning

confidence: 98%

Implication of inflammatory cytokines in the aqueous humour for management of macular diseases

Qian¹,

Wang²,

Chen³

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Previous studies focused on ranibizumab, aflibercept and bevacizumab had reported similar findings ( El Chehab et al, 2016 ; Kato et al, 2019/05 ; Fuest et al, 2014 ). To the best of our knowledge, there is only one study reporting the changes of IOP after IVI of Conbercept ( Zhang et al, 2016 ). However, the main purpose of the study was to evaluate the influence of increased IOP on retinal nerve fiber thickness in a long-term basis.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of short-term intraocular pressure changes after intravitreal injection of Conbercept in patients with diabetic macular edema

Zeng

Yang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The study concerning the influence of Conbercept, which is an anti-Vascular endothelial growth factor (VEGF) agent, in intraocular pressure (IOP) spike is limited and warrants further investigation. The current study aimed to investigate the changes of intraocular pressure after intravitreal injection (IVI) of Conbercept and evaluate the risk factors associated with intraocular pressure spikes.Methods: Patients with diabetic macular edema receiving intravitreal injection of 0.05 ml (0.5 mg) Conbercept were involved in the study. All patients underwent slit lamp examination to determine the status of phakia/pseudophakia. The axial length was measured using IOL Master 500 before intravitreal injection. Patients underwent a Conbercept intravitreal injection with a 30-gauge needle in a standard fashion. The intraocular pressure was measured 2 min before injection, and 2, 10, 30 min, 1, 2, 5, 24 h after injection using a rebound tonometer. The changes of intraocular pressure and the relevant risk factors were evaluated. Patients were subdivided into phakic group and pseudophakic group to analyze the effect of lens status on intraocular pressure changes.Results: Forty patients with a mean age of 62.48 ± 12.22 years were included in the study. The mean intraocular pressure values at baseline and 2, 10, 30 min, 1, 2, 5, 24 h after injection were 14.81 ± 3.13 mmHg, 26.80 ± 9.43 mmHg, 18.76 ± 6.16 mmHg, 16.54 ± 5.94 mmHg, 15.64 ± 3.75 mmHg, 14.46 ± 3.03 mmHg, 14.10 ± 1.88 mmHg, 14.23 ± 2.71 mmHg respectively. The intraocular pressure after injection for 2, 10 min was significantly higher than baseline (p < 0.001, p = 0.001, respectively). The intraocular pressure between baseline and post-injection for 30 min or beyond were comparable (all p > 0.05). No significant difference was found between the phakic group and pseudophakic group (p = 0.422). The changes of intraocular pressure were positively correlated with age (r = 0.329, p = 0.038), but negatively with axial length (r = −0.472, p = 0.002).Conclusion: intravitreal injection of Conbercept may cause rapid spike of intraocular pressure, but is safe with respect to short-term changes. The intraocular pressure in patients with older age and shorter axial length is more likely to be higher after intravitreal injection.

show abstract

“…Conbercept (KH902; Chengdu Kanghong Biotech Co., Ltd., Sichuan, China) is a recombinant fusion protein that was designed as a receptor decoy and has high affinity for all VEGF isoforms and placental growth factor (PlGF) [13]; it is widely used in anti-VEGF therapy in China [14, 15]. To the best of our knowledge, no study has examined the effect of conbercept on individual layer changes in DME treatment.…”

Section: Introductionmentioning

confidence: 99%

Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment

Yuan

Sai

et al. 2019

BMC Ophthalmol

Self Cite

View full text Add to dashboard Cite

Backgrounds To assess the changes in individual retinal layer thickness and visual function associated with gains in visual acuity after an intravitreal conbercept injection in the diabetic macular edema (DME) on spectral domain optical coherence tomography (SD-OCT) and microperimetry during 1-year follow-up. Methods Retrospective observational study. Twenty patients with clinically significant DME in the study eye were imaged by SD-OCT every 3 months and MP1 microperimeter in the third month while receiving anti-vascular endothelial growth factor (VEGF) (conbercept) treatment. In each patient, seven retinal layers were segmented in 98 scans covering a 6 mm × 6 mm area of the macula at baseline and during 1 year of treatment. An automatic, full-threshold microperimetry of the central field (10° × 10°, 40 stimulated points) with the MP1 microperimeter. Thickness and microperimetry changes were quantitatively measured and evaluated for their correlation with increases in visual acuity. Results Although thicknesses of the inner nuclear layer (INL) and the outer nuclear layer (ONL) were reduced the most after treatment ( p < 0.05), decreases of the ganglion cell layer (GCL) ( r = 0.591, p = 0.006) and inner plexiform layer (IPL) ( r = 0.663, p = 0.001) in central subfield area was associated with best-corrected visual acuity (BCVA) gain, and had the best estimation of BCVA gain (adjust R 2 = 0.544). Mean macular sensitivity in the central subfield was also well correlated with BCVA gain ( r = 0.531, p = 0.016). Conclusions Neural recovery occurred after the resolution of edema during conbercept treatment, due to the decreases in GCL and IPL associating with gains in vision and improved microperimetry. Electronic supplementary material The online version of this article (10.1186/s12886-019-1131-0) contains supplementary material, which is available to authorized users.

show abstract

Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases

Cited by 10 publications

References 25 publications

Implication of inflammatory cytokines in the aqueous humour for management of macular diseases

Implication of inflammatory cytokines in the aqueous humour for management of macular diseases

Evaluation of short-term intraocular pressure changes after intravitreal injection of Conbercept in patients with diabetic macular edema

Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment

Contact Info

Product

Resources

About